Fig. 4: Tissue persistence of RQ-01 administered intranasally. | Nature Communications

Fig. 4: Tissue persistence of RQ-01 administered intranasally.

From: A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential

Fig. 4

a Mice were treated intranasally with 1, 3, or 10 mg/kg of RQ-01 formulated in 0.1% HPMC/50 mM sodium phosphate, pH 6.5 and sacrificed at 2, 4, 7, or 24 h for PK analysis, performed by LC/MS-MS of nasal tissue homogenates. Data are mean ± SEM for drug levels quantified for n = 3 mice per dosing level and time point. b Mice were treated intranasally with 2 mg/kg of RQ-01 formulated in 0.9% saline, pH 7.2, and sacrificed at 0.5, 1, 2, 4, 8, 24, and 48 h after dosing for PK analysis, performed by LC/MS-MS of nasal and lung tissue homogenates. Data are mean ± SEM for drug levels quantified for n = 3 mice per dosing level and time point.

Back to article page